¹þ¹þÌåÓý

¹þ¹þÌåÓý¿Æ¼¼Ó뿵ϣŵÉúÎï¸æ¿¢Õ½ÂÔÏàÖú ¹²Ì½mRNAÒßÃçÖ×ÁöÃâÒßмƻ®

2025-04-10

×ÖºÅ

       ¿ËÈÕ£¬£¬£¬£¬£¬ £¬¹þ¹þÌåÓý¿Æ¼¼È«×Ê×Ó¹«Ë¾Ìì½ò¹þ¹þÌåÓý¿Æ¼¼ÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°¹þ¹þÌåÓý¿Æ¼¼¡±£©Ó뿵ϣŵÉúÎï×Ó¹«Ë¾¿µÏ£ÅµÉúÎÉϺ££©ÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°¿µÏ£ÅµÉúÎ£©Ç©ÊðÏàÖú¿ª·¢Ð­Ò飬£¬£¬£¬£¬ £¬Ë«·½½«ÅäºÏÍƽømRNAÒßÃçÓÃÓÚÖÎÁƽºÖÊĸϸ°ûÁö£¨GBM£©µÄÁÙ´²Ñо¿ÏîÄ¿£¬£¬£¬£¬£¬ £¬Ô¤¼Æ½ñÄêÄÚÍê³ÉÊ×Àý»¼Õ߸øÒ©¡£¡£ ¡£¡£

       ¹þ¹þÌåÓý¿Æ¼¼ºÍ¿µÏ£ÅµÉúÎïͬΪÌì½òºËËṤҵͬÃ˵ijÉÔ±µ¥Î»£¬£¬£¬£¬£¬ £¬´ËÇ°Ë«·½ÔÚÒªº¦ÖÊÁÏÑз¢¼°½¹µãÊÖÒÕ֪ʶ²úȨ½á¹¹µÈÁìÓòÒѽ¨ÉèÓÅÒìÏàÖú»ù´¡¡£¡£ ¡£¡£±¾´ÎÏàÖú½«³ä·ÖÑéÕ¹¹þ¹þÌåÓý¿Æ¼¼ÔÚ¿¹Ö×ÁöÒ©Î￪·¢µÄ¸»ºñÂÄÀúÓ뿵ϣŵÉúÎïmRNAÊÖÒÕƽ̨µÄÐÛºñʵÁ¦£¬£¬£¬£¬£¬ £¬Í¬Ê±Ò²ÎªË«·½ÔÚmRNAÒßÃçÖÎÁÆÖ×ÁöÁìÓòÉîÈë½»Á÷ºÍ½øÒ»²½ÏàÖúµÓÚ¨»ù´¡¡£¡£ ¡£¡£

       ¹þ¹þÌåÓý¿Æ¼¼ÖÕÄêרעÓÚÒ©ÎïµÝËÍÁìÓò£¬£¬£¬£¬£¬ £¬ÔÚÖ×ÁöÃâÒß·½ÃæºÍmRNAµÝË͵ÈÆ«Ïò¾ùÓнṹ¡£¡£ ¡£¡£¹þ¹þÌåÓý¿Æ¼¼×ÔÖ÷Ñз¢µÄ¾ÛÒÒ¶þ´¼ÒÁÁ¢Ì濵(JK1201I)ÖÎÁÆÒ»ÏßÏ£ÍûÆÕ±éÆÚСϸ°û·Î°©ÕýÔÚ¾ÙÐÐÁÙ´²ÈýÆÚÑо¿£¬£¬£¬£¬£¬ £¬ÄÔ½ºÖÊÁö˳Ӧ֢Óë°éÄÔתÒƵÄÈýÒõÐÔÈéÏÙ°©Ë³Ó¦Ö¢ÕýÔÚ¾ÙÐÐÁÙ´²¶þÆÚÑо¿¡£¡£ ¡£¡£

       ¿µÏ£ÅµÉúÎｨÉèµÄmRNAÊÖÒÕƽ̨£¬£¬£¬£¬£¬ £¬ÓµÓÐ×ÔÖ÷Éè¼Æ¡¢¿ª·¢µÄÐòÁÐÓÅ»¯Èí¼þ£¬£¬£¬£¬£¬ £¬¿É»ñµÃÓ°ÏìÎȹÌÐÔµÄÒªº¦Î»µã¼°ÓÐÓÃÌá¸ß¿¹Ô­±í´ïÁ¿µÄ×îÓÅÐòÁУ¬£¬£¬£¬£¬ £¬CMC¹¤ÒÕ¾«Á·£¬£¬£¬£¬£¬ £¬¿ÉÒÔËõ¶Ì²úÆ·¿ª·¢Ê±¼ä£¬£¬£¬£¬£¬ £¬¿ìËÙʵÏÖ¿ÆÑÐЧ¹û¹¤Òµ»¯¡£¡£ ¡£¡£

       ¹þ¹þÌåÓý¿Æ¼¼½«ÒÀÍÐmRNAµÈÏȽøÊÖÒÕƽ̨£¬£¬£¬£¬£¬ £¬³Ð¼ÌÒÔÖÊÁÏÁ¢ÒìÒýÁìÉúÎïÒ½Ò©Á¢ÒìµÄʹÃü£¬£¬£¬£¬£¬ £¬Ò»Á¬Í¨¹ýÐÂÐÍÒ©ÎïµÝËÍÊÖÒÕΪÖ×ÁöÃâÒß¡¢»ùÒòÖÎÁƵÈÁìÓò´øÀ´¸ü¶àÓÐÖúÓÚÈ«·½Î»ÌáÉý»¼Õ߸£ÀûµÄ½â¾ö¼Æ»®£¬£¬£¬£¬£¬ £¬Ð¯ÊÖЭ×÷ͬ°éÅäºÏÔö½ø¡°ÈËÈËÏíÓÐÎÀÉú¿µ½¡¡±Ä¿µÄµÄʵÏÖ¡£¡£ ¡£¡£

 

¹ØÓÚ½ºÖÊĸϸ°ûÁö

½ºÖÊĸϸ°ûÁö£¨Ò²³ÆΪ¢ô¼¶ÐÇÐÎϸ°ûÁö£©ÊÇÌìÏÂÎÀÉú×éÖ¯È϶¨µÄIV¼¶½ºÖÊÁö£¬£¬£¬£¬£¬ £¬Ò²ÊÇ×î³£¼ûµÄ¶ñÐÔÔ­·¢ÐÔÄÔÖ×Áö£¬£¬£¬£¬£¬ £¬5ÄêÉúÑÄÂÊΪ7.2%¡£¡£ ¡£¡£¸ÃÖ×ÁöÉú³¤Ñ¸ËÙ£¬£¬£¬£¬£¬ £¬¶ñÐԶȸߣ¬£¬£¬£¬£¬ £¬Ö÷ҪλÓÚ´óÄÔ°ëÇò£¬£¬£¬£¬£¬ £¬Ò²¿É±¬·¢ÔÚÄԸɡ¢Ð¡ÄÔ°ëÇò»ò¼¹ËèµÈ£¬£¬£¬£¬£¬ £¬Ö÷Òª·¢²¡ÄêËêΪ45-60Ë꣬£¬£¬£¬£¬ £¬ÄÐÐÔ½ÏÅ®ÐÔ·¢²¡ÂÊÂԸߣ¬£¬£¬£¬£¬ £¬¶ùͯҲ¿ÉÒÔ·¢²¡£¬£¬£¬£¬£¬ £¬ÇÒ¶à¼ûÓÚÄԸɡ£¡£ ¡£¡£GBMµÄ¸ß¶È½þÈóÐÔ¡¢ÒÅ´«ÒìÖÊÐÔºÍѪÄÔÆÁÕϵı£»£»£»¤¸øÖÎÁÆ´øÀ´ÁËÖØ´óµÄÌôÕ½¡£¡£ ¡£¡£ÏÖÔÚGBMµÄ±ê×¼ÖÎÁÆÊÇÊÖÊõÇгýºó¾ÙÐзŻ¯ÁÆ¡£¡£ ¡£¡£ÊÖÊõÇгýÖ×Áöºó¸´·¢½Ï¿ì£¬£¬£¬£¬£¬ £¬ÆäÔ¤ºóÊÇÄÔ½ºÖÊÁöÖнϲîµÄÒ»ÖÖ¡£¡£ ¡£¡£¡¾1¡¿

½üÄêÀ´ÃâÒßÁÆ·¨³ÉΪÐí¶àÖ×ÁöµÄÖ÷ÒªÖÎÁÆ·½·¨£¬£¬£¬£¬£¬ £¬¿ÉÊÇÔÚÄÔ°©£¨°üÀ¨GBM£©µÄÖÎÁÆÉÐδȡµÃÍ»ÆÆ¡£¡£ ¡£¡£È¥ÄêÍâÑó¼¸ÏîʹÓÃmRNAÒßÃçµÄСÐÍÁÙ´²ÊÔÑéµÄЧ¹ûËƺõŤתÁËÕâÒ»Ç÷ÊÆ£¬£¬£¬£¬£¬ £¬Ïà¹ØµÄÑо¿±¨µÀÔÚNIHÉÏÓÐËù±¨µÀ[2]¡£¡£ ¡£¡£Í¬Äêһƪ½ÒÏþÔÚJ NanobiotechnologyµÄ×ÛÊö»ã×ÜÁËmRNAÒßÃçÔÚGBMµÄÓ¦Óá¾3¡¿£¬£¬£¬£¬£¬ £¬Õ¹Ê¾ÁËÖ÷ÒªµÄÖÎÁÆDZÁ¦¡£¡£ ¡£¡£

 

¹ØÓÚ¹þ¹þÌåÓý¿Æ¼¼

¹þ¹þÌåÓý£¨¹þ¹þÌåÓý¿Æ¼¼688356.SH£©½¨ÉèÓÚ2001Ä꣬£¬£¬£¬£¬ £¬ÊÇÈ«ÇòÒ½ÓÃÒ©ÓþÛÒÒ¶þ´¼ÖÊÁÏÁìÓòµÄÖ÷ÒªÐÂÐ˼ÓÈëÕߣ¬£¬£¬£¬£¬ £¬Îª¶à¿îÉÏÊÐPEG»¯Á¢ÒìÒ©Îï¼°Ò½ÁÆÆ÷е²úÆ·¹©Ó¦PEGÑÜÉúÎï¡£¡£ ¡£¡£Í¬Ê±¿ª·¢Á˺£ÄÚµÚÒ»¿îPEGżÁªÐ¡·Ö×ÓÒ©Î£¬£¬£¬£¬ £¬ÏÖÔÚ¸ÃÏîÄ¿´¦ÓÚÈýÆÚÁÙ´²½×¶Î¡£¡£ ¡£¡£¹þ¹þÌåÓý¿Æ¼¼¾Û½¹mRNAµÝËÍϵͳ½¹µãÊÖÒÕ¹¥¹Ø£¬£¬£¬£¬£¬ £¬ÔÚÒªº¦Ö¬ÖÊÖÊÁÏÁìÓòÈ¡µÃÖ÷ҪͻÆÆ£ºÍ¨¹ý¶ÔÏÖÓеÝËÍϵͳÖÐÒªº¦Ö¬ÖÊÒòËؾÙÐÐÉú²ú¹¤ÒÕÓÅ»¯£¬£¬£¬£¬£¬ £¬ÊµÏÖÁË5ÖÖÒªº¦¸¨ÁϵĹæÄ£»£»£»¯×ÔÖ÷ÖƱ¸£¬£¬£¬£¬£¬ £¬Ïà¹ØÊÖÒÕ×ÊÁÏÒÑͨ¹ý¹ú¼ÒÒ©¼à¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©ºÍÃÀ¹úFDAµÄÖÊÁÏÒ©Ö÷Îļþ£¨DMF£©Ë«Öر¸°¸£»£»£»Í¬²½¹¹½¨ÁË°üÀ¨ÊýÊ®ÖÖÁ¢Òì½á¹¹µÄÖ¬ÖÊ»¯ºÏÎï¿â£¬£¬£¬£¬£¬ £¬ÐγɾßÓÐ×ÔÖ÷֪ʶ²úȨµÄÊÖÒÕ¾ØÕ󡣡£ ¡£¡£

 

¹ØÓÚ¿µÏ£ÅµÉúÎï

¿µÏ£ÅµÉúÎï¹É·Ý¹«Ë¾£¨¿µÏ£ÅµÉúÎï 06185.HK£»£»£»¿µÏ£Åµ 688185.SH£©£¬£¬£¬£¬£¬ £¬2009Ä꽨ÉèÓÚÖйú£¬£¬£¬£¬£¬ £¬ÖÂÁ¦ÓÚÔÚÌìϹæÄ£ÄÚÌṩԤ·ÀºÍÖÎÁÆѬȾÀ༲²¡µÄ½â¾ö¼Æ»®¡£¡£ ¡£¡£¹«Ë¾ÏÖÓв¡¶¾ÔØÌåÒßÃçÊÖÒÕ¡¢ºÏ³ÉÒßÃçÊÖÒÕ¡¢ÂѰ׽ṹÉè¼ÆºÍVLP×é×°ÊÖÒÕ¡¢mRNAÊÖÒÕ¡¢ÖƼÁ¼°¸øÒ©ÊÖÒÕÎå´óÁ¢ÒìÒßÃçƽ̨ÊÖÒÕ¡£¡£ ¡£¡£ÏÖÔÚÒѽ¨ÉèÁýÕÖ10ÓàÖÖ˳Ӧ֢µÄ¶à¿îÁ¢ÒìÒßÃç²úÆ·£¬£¬£¬£¬£¬ £¬°üÀ¨ÑÇÖÞÊ׿îËļÛÁ÷ÄÔÁ¬ÏµÒßÃçÂüº£ÐÀ?¡¢¶þ¼ÛÁ÷ÄÔÁ¬ÏµÒßÃçÃÀÄÎϲ?¡¢»ñµÃÊÀÎÀ×éÖ¯ÈϿɵÄйÚÒßÃç¿ËÍþɯ?¡¢È«ÇòÊ׿îÎüÈëÓÃйÚÒßÃç¿ËÍþɯ?ÎíÓÅ?ÒÔ¼°ÑÇÖÞÊ׸öÖØ×é°£²©À­²¡¶¾²¡ÒßÃç¡£¡£ ¡£¡£

 

Reference

[1] Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021 Sep;171:105780. doi: 10.1016/j.phrs.2021.105780. Epub 2021 Jul 21. PMID: 34302977; PMCID: PMC8384724.

[2] mRNA Vaccine Boosts Immune Response Against Glioblastoma - NCI

[3] Karimi-Sani I, Molavi Z, Naderi S, Mirmajidi SH, Zare I, Naeimzadeh Y, Mansouri A, Tajbakhsh A, Savardashtaki A, Sahebkar A. Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials. J Nanobiotechnology. 2024 Oct 4;22(1):601. doi: 10.1186/s12951-024-02882-x. PMID: 39367418; PMCID: PMC11453023.

Òªº¦´Ê£º

ÉÏÒ»Ò³

ϲ±¨ | ¹þ¹þÌåÓý¿Æ¼¼£¨688356.SH£©×¢ÉäÓý»ÁªÍ¸Ã÷ÖÊËáÄÆÄý½º²úÆ·»ñÅúÈýÀàÒ½ÁÆÆ÷еע²áÖ¤

¹þ¹þÌåÓý¿Æ¼¼£¨688356.SH£©KT-001ºÍHO-PEG2000-DMG»®·Öͨ¹ýFDA¡¢CDE±¸°¸

ÏÂÒ»Ò³

ÉÏÒ»Ò³£º

ϲ±¨ | ¹þ¹þÌåÓý¿Æ¼¼£¨688356.SH£©×¢ÉäÓý»ÁªÍ¸Ã÷ÖÊËáÄÆÄý½º²úÆ·»ñÅúÈýÀàÒ½ÁÆÆ÷еע²áÖ¤

ÏÂÒ»Ò³£º

¹þ¹þÌåÓý¿Æ¼¼£¨688356.SH£©KT-001ºÍHO-PEG2000-DMG»®·Öͨ¹ýFDA¡¢CDE±¸°¸

ÍƼöÐÂÎÅ

¡¾¹þ¹þÌåÓý¿Æ¼¼×¨Ìâ·ÖÏí¡¿ÓëÄúÏàÔ¼6ÔÂCPHIÖÆÒ©ÖÊÁÏÖÇÔ칤ҵÂÛ̳

2025-06-09

ϲ±¨ | ¹þ¹þÌåÓý¿Æ¼¼£¨688356.SH£©×¢ÉäÓý»ÁªÍ¸Ã÷ÖÊËáÄÆÄý½º²úÆ·»ñÅúÈýÀàÒ½ÁÆÆ÷еע²áÖ¤

2025-04-27

¹þ¹þÌåÓý¿Æ¼¼£¨688356.SH£©KT-001ºÍHO-PEG2000-DMG»®·Öͨ¹ýFDA¡¢CDE±¸°¸

2025-03-06

·ÖÏíµ½

¡¾ÍøÕ¾µØͼ¡¿